Doctors Find Less Need For Abbott's 'Good Cholesterol' Pill - Forbes

Forbes

Doctors Find Less Need For Abbott's 'Good Cholesterol' Pill Forbes The brand name, known as Niaspan, was not long ago an increasingly used treatment in a physician's prescribing arsenal to protect against heart disease. So much was the case that Niaspan, the extended release formulation of generic niacin, ... and more »

Genetic study questions HDL levels and the risk of MI - TheHeart.Org

AFP

Genetic study questions HDL levels and the risk of MI TheHeart.Org Boston, MA - Therapies that boost HDL-cholesterol levels are currently viewed as a potential treatment to close down the residual risk of aggressively treated patients, but data from a new study throw cold water on the putative benefits of raising ... Study questions whether raising “good" cholesterol reduces heart attack riskBoston.com Raising HDL Levels May Not Lower Heart Attack RiskWebMD all 139 news articles »

Statins could benefit everyone over 50, study suggests - CTV.ca

CTV.ca

Statins could benefit everyone over 50, study suggests CTV.ca The study was written by a group called the Cholesterol Treatment Trialists' (CTT) Collaborators. Some members of the team have been compensated to participate in scientific meetings from the pharmaceutical industry. The study was funded by the British ... and more »

Advanced Atherosclerosis: The Heart and Beyond - Medscape

Advanced Atherosclerosis: The Heart and Beyond Medscape In such populations, there tends to be high residual risk, even in aggressively treated patients. The premise of AIM-HIGH was to see if adding extended-release niacin to raise HDL cholesterol in patients who had already achieved a very low LDL ... and more »

Roche Drug to Raise 'Good' Cholesterol Fails - Wall Street Journal

Wall Street Journal

Roche Drug to Raise 'Good' Cholesterol Fails Wall Street Journal Last year, Abbott Laboratories' niacin-based drug called Niaspan in a large study failed to prevent heart attacks and strokes when added to statin treatment, even though the compound raised HDL. Despite such headwinds, Merck and Lilly said Monday that ... and more »